|How is pancreatic cancer detected or screened?||Clinical trials|
|Choosing your cancer care center wisely||Guidelines|
|Approaches for treating pancreatic cancer||Questions for your doctor|
|What does this mean for me?||Resources|
PANCREATIC CANCER AT A GLANCE
In 2020, the impact of pancreatic cancer received much-needed media attention due to the passing of U.S. Supreme Court Justice Ruth Bader Ginsberg, U.S. House of Representative member John Lewis and Jeopardy! game show host Alex Trebek—who all died from the disease that year. They were preceded by many well-known figures including Dizzy Gillespie, Sharon Jones and Alan Rickman, profiled by WebMD to highlight the impact of this disease.
Although pancreatic cancer is rare, it is the third leading cause of cancer-related death in the United States, claiming more than 47,000 lives in 2020 and is projected to be the second leading cause of cancer deaths by 2030. The American Cancer Society estimates that more than 60,000 people in the United States will be diagnosed with pancreatic cancer in 2021.
Pancreatic cancer develops in the pancreas, an organ that aids in the digestion of food and the breakdown of sugar. The pancreas is located behind the stomach and around the upper portion of the small intestine. Pancreatic cancer starts when mutated cells of the pancreas begin to grow uncontrollably and begin to form a tumor (a mass of cells).
Because the pancreas is located behind the stomach, early tumors are not easily seen or felt by healthcare providers during routine physical exams. People with pancreatic cancer usually have no symptoms until the cancer has become very large or has already spread (metastasized) to other organs. More than half (52 percent) of all pancreatic cancer cases are diagnosed as metastatic cancer and another third are found when the cancer is inoperable. In all of these situations, the cancer is diagnosed at a point where it is treatable, but incurable.
Screening for pancreatic cancer can be done using a type of ultrasound known as esophageal ultrasound (EUS) or a type of magnetic resonance imaging (MRI) known as magnetic resonance cholangiopancreatography (MRCP). Because pancreatic cancer is considered rare, screening is not usually recommended for the general public. Expert guidelines recommend screening only for people at high risk, including those with a strong family history of the disease or with a known inherited mutation that increases their risk of pancreatic cancer.
Pancreatic cancer tends to be aggressive—even when diagnosed at early stages—which makes it difficult to treat. Only 11 percent of people with pancreatic cancer are expected to live five years after their initial diagnosis. However, the chance of surviving up to five years is increased about fourfold with early detection, which also allows for better treatment outcomes.
Andrew M. Lowy, M.D., Chief, Division of Surgical Oncology at the Moores Cancer Center at University of California San Diego Health, spoke with CURE magazine about current pancreatic cancer treatments and drugs that are being studied in clinical trials to better treat the disease.
“Pancreatic cancer is a complex disease,” said Dr. Lowey in the interview. “Patients (with pancreatic cancer) face several issues that range from managing their therapy, whether it be chemotherapy, radiation therapy or surgery, to managing other medical aspects.”
To help address these concerns, multiple healthcare professionals need to be involved in your cancer care. These multidisciplinary teams of professionals are more likely to be found at academic cancer centers that have expertise in treating pancreatic cancer. Pancreatic patients whose care is managed by a multidisciplinary team are likely to live an average of seven months longer than pancreatic patients who are not treated this way.
A multidisciplinary team may include the following health professionals:
|Gastroenterologist||Physician who treats the digestive system.||Dietician/ nutritionist||Provides guidance on foods/diets that are suitable for your condition.|
|Medical oncologist||Physician who treats cancer using systemic therapy.||Pathologist||Studies the cells, tissues and organs removed during a biopsy or surgery|
|Oncology nurses||Provides hands-on care, gives systemic therapy and helps with side effect management.||Genetic
|Determine need for and interprets genetic testing to assess your risk for inherited cancers.|
|Palliative care nurses/providers||Provides treatment for cancer-related symptoms.||Radiation oncologist||Physician who prescribes and plans radiation therapy to treat cancer or symptoms.|
|Anesthesiologist||Physician who gives anesthesia, a medicine that prevents you from feeling pain during surgery.||Surgical
|Physician who performs operations to remove cancer.|
|Diagnostic radiologist||Physician who interprets results of x-rays and other imaging tests.||Mental health professionals (e.g., psychiatrists, psychologists, social workers)||Professionals who help manage issues such as depression, anxiety, or mental health conditions that affect how you feel emotionally.|
|Clinical Research Coordinator||Expertise in clinical research and clinical trials for new therapies||Oncology pharmacist||
Pharmacist with specialty training in optimizing medications to treat cancer and minimize side effects or medication interactions.
Pancreatic cancer is treated with multiple therapies, including surgery (partial or total removal of the pancreas) or chemotherapy. “Like all cancers, the treatment selection is based on stage,” Dr. Lowy says. “However, what’s different about pancreatic cancer is because it’s such an aggressive disease, every patient essentially will get chemotherapy at some point in their care.”
Chemotherapy is a drug treatment that uses chemicals to kill fast-growing cancer cells. According to Dr. Lowy, the best outcomes for treating pancreatic cancer are achieved when people receive chemotherapy in addition to surgery. Chemotherapy can be given as neoadjuvant therapy (before surgery) or as an adjuvant therapy (after surgery).
In the past, chemotherapy was often prescribed only after surgery in patients with early-stage disease to kill any remaining cancer cells. However, Dr. Lowy explains, this traditional approach has many disadvantages. “The thing to understand is that pancreas surgery is very complex. Despite the fact that we’ve gotten better at it, it is associated with a high complication rate. [It can take patients time] to recover from the operation to be able to get their chemotherapy. And so, by giving chemotherapy before the operation, when people are still in good shape before they have to undergo a surgical recovery, it ensures that we get that chemotherapy delivered.”
Dr. Lowy also notes that for people whose cancer has spread beyond the pancreas (advanced cancer), giving chemotherapy before surgery can determine if they will be a good candidate for the operation. If chemotherapy is successful in getting rid of cancer in other areas of the body, then that person would be considered a good candidate for surgery. If not, then surgery would not be considered beneficial.
Currently, three standard chemotherapy regimens are used to treat newly diagnosed pancreatic cancer. These include FOLFIRINOX (a combination of folinic acid, 5-fluorouracil, irinotecan and oxaliplatin), a combination of gemcitabine and nanoparticle albumin bound (nab)-paclitaxel (Abraxane), and Lynparza (a targeted PARP inhibitor also called olaparib). FOLFIRINOX is intravenous and usually given to people who are in good health due to its associated side effects. Gemcitabine and Abraxane is also intravenous and typically has fewer/different side effects than FOLFIRINOX so is favored if the patient who are not as healthy. Lynparza is a pill but is only offered to those people whose cancer is due to underlying BRCA1, BRCA2 or PALB2 mutations.
Targeted and immunotherapies
Although not a focus in the CURE article, it’s important to note that newer, targeted therapies and immunotherapies may be available to treat certain types of pancreatic cancer. The PARP inhibitor olaparib (Lynparza) is approved for maintenance therapy (after chemotherapy) for people with an inherited BRCA1 or BRCA2 mutation whose cancer responded to platinum chemotherapy.
Tumor biomarker testing should also be used to try to identify other possible treatments for pancreatic cancer. For example, tumors that have the traits of deficient DNA mismatch repair (dMMR) or are microsatellite instability high (MSI-High) or have a high tumor mutation burden on genomic profiling may respond to a type of immunotherapy known as immune checkpoint inhibitors. Pembrolizumab (Keytruda) is an immunotherapy drug with FDA approval for treating MSI-High cancers regardless of what organ the cancer came from.
According to Dr. Lowy, more therapies to treat pancreatic cancer are being tested in current clinical trials than any other time in history, and these therapies span different drug classes. The therapies include immunotherapies (drugs that prompt that your immune cells to fight cancer), cancer metabolism drugs (drugs that block cancer cell growth by cutting it off its energy source) and targeted therapies (drugs that target specific genes or the genetic material of certain cancer cells).
“Some of these drugs may be approved as soon as 2022 if they show effectiveness in treating pancreatic cancer,” Lowey concludes. It is also important to consider that treatment of pancreatic cancer on a clinical trial, even if the clinical trial includes standard therapies, is associated with improved survival and other important clinical outcomes for patients. This is related to the extra attention to detail, coordinated services and expertise involved in treatment delivery on a clinical trial.
Some inherited mutations increase the risk of pancreatic cancer
Some inherited mutations, including ATM, BRCA1, BRCA2, CDKN2A, MLH1, STK11, TP53 and others, have been linked to an increased risk for pancreatic cancer.
The Lynch syndrome gene MLH1 has been linked to an increased risk of pancreatic cancer. However, more research is needed to confirm whether a link exists between other Lynch syndrome genes (EPCAM, MSH2, MSH6, PMS2) and pancreatic cancer.
If you have been diagnosed with pancreatic cancer, it is important to be selective about the facility you choose to receive treatment. This will ensure that you get the most effective and up-to-date treatment regimen for your disease. It is important to speak with your doctor about all options that are available to you, including a multidisciplinary team, treatments, and any clinical trials that may be beneficial for your cancer care.
If pancreatic cancer runs in your family or you have an inherited mutation linked to pancreatic cancer risk, you should speak to experts in genetics and in pancreatic cancer detection to see if you qualify for pancreatic cancer screening or a clinical research study.
Share your thoughts on this XRAY review by taking our brief survey.
- Kahl K, Know Your Options When It Comes to Pancreatic Cancer. The Cure. February 12, 2021.
- 16 Celebrities With Pancreatic Cancer. WebMD. May 23, 2021.
- Hoehn R, Rieser C, Winters S, et al. A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Ann Surg Oncol. 2021 May;28(5):2438-2446. Published online February 1, 2021
FORCE receives funding from industry sponsors, including companies that manufacture cancer drugs, tests and devices. All XRAYS articles are written independently of any sponsor and are reviewed by members of our Scientific Advisory Board prior to publication to assure scientific integrity.
The National Comprehensive Cancer Network (NCCN) recommends the following screening for people at increased risk for pancreatic cancer:
- Discuss the benefits and risks of screening with their doctor. Screening should be performed by a facility that is experienced with screening for pancreatic cancer. The recommended age for considering screening depends on a person’s family history of pancreatic cancer and varies by type of gene mutation.
- Consider screening with magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasound (EUS)
- Consider participating in a pancreatic cancer screening study
NCCN recommends that people with inherited mutations in the following genes (with or without a family history of cancer) "consider pancreatic cancer screening" with MRCP or EUS:
- STK11: (Peutz-Jeghers syndrome): Consider pancreatic cancer screening by MRCP or EUS every 1-2 years beginning at age 30-35 or 10 years younger than the earliest pancreatic cancer in the family.
- CDKN2A: Consider pancreatic cancer screening beginning at age 40 or 10 years earlier than the earliest pancreatic cancer diagnosis in the family.
NCCN guidelines recommend that people with an inherited mutation in one of the following genes and a family history of cancer "consider pancreatic cancer screening" with MRCP or EUS beginning at age 50 or 10 years earlier than the earliest pancreatic cancer diagnosis in the family: ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, EPCAM, PALB2, TP53.
NCCN does not currently recommend pancreatic cancer screening for people with the above mutations who do not have a family history of cancer.
The National Comprehensive Cancer Network (NCCN) recommends the following for people diagnosed with pancreatic cancer:
- Receive treatment from a multidisciplinary team (MDT): Treatment decisions should involve an MDT that includes a team of doctors, healthcare workers, genetic counselors and mental health professionals who have expertise and experience with treating and addressing issues related to your type of cancer. MDTs are more likely to be found or affiliated with cancer centers that have experience in treating pancreatic cancer.
- Have tumors staged via imaging tests: Staging is needed to plan and monitor your treatment. Imaging tests (e.g., tomography scans) are used to stage pancreatic cancer. The tests determine whether the tumor can be removed with surgery (resectable) if cancer has spread to nearby organs or lymph nodes (locally advanced) or has spread to other parts of the body (metastasized).
- Discuss with your healthcare team whether they recommend chemotherapy before and/or after your surgery.
- Have genetic testing, using a comprehensive gene panel for hereditary cancer (this applies to anyone who is diagnosed with pancreatic cancer).
- Genetic testing results may be used in making treatment decisions.
- Have tumor testing (for people with locally advanced or metastatic pancreatic cancer).
- Tumor testing results can also be used in making treatment decisions.
- Keep a copy of all test results (online patient portals are a great way to access test results). This will come in handy during a second opinion, if necessary.
- Do I qualify for any pancreatic cancer clinical trials?
- How do I obtain tumor testing of my cancer to look for specific treatment options?
- Should I consider genetic testing for an inherited mutation?
- Given my family history, do I qualify for pancreatic cancer screening?
- Which healthcare professionals will be involved in my cancer care?
- Will surgery be beneficial for me?
- What side effects are associated with my cancer treatment(s)?
The following are studies looking at risk management for pancreatic cancer:
- NCT03250078: A Pancreatic Cancer Screening Study in Hereditary High-Risk Individuals. The main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early-stage pancreatic cancer or precursor lesions.
- NCT02478892: Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk. The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM or PALB2 mutations.
- NCT03568630: Blood Markers of Early Pancreas Cancer. Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease.
- NCT02206360: Pancreatic Cancer Early Detection Program (PCEDP). This is a study looking at esophageal ultrasound as a screening for pancreatic cancer in high risk individuals.
- NCT03250078: A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals. The goal is to screen for pancreatic cancer in individuals with a strong family history or genetic risk using Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP).
A number of other clinical trials for pancreatic cancer screening and prevention may be found here.
The following are studies enrolling people diagnosed with pancreatic cancer:
- NCT04229004: Precision Promise Platform Trial for Metastatic Pancreatic Cancer. This study tests different treatments for metastatic pancreatic cancer.
- NCT04267939: ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer. This study will look at how well how well advanced solid tumors respond to treatment with the targeted therapy BAY1895344 combined with the PARP inhibitor niraparib.
- NCT04493060: Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab. This study looks at how well the PARP inhibitor niraparib and the immunotherapy drug dostarlimab work together in treating patients with metastatic pancreatic cancer, who have an inherited or tumor mutation in one of these genes: BRCA1, BRCA2, PALB2, BARD1, RAD51c, or RAD51d.
- NCT03337087: Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Chemotherapy and Rucaparib This study will look at how the targeted therapy rucaparib works with chemotherapy in treating patients with metastatic pancreatic, colorectal, gastroesophageal or biliary cancer. The study will measure the best dose and look at side effects with this combination of drugs.
- NCT04150042: A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C and Stem Cell Infusion in People with Advanced Pancreatic Cancer and BRCA Mutations. This study will look at whether combining melphalan, BCNU, vitamin B12b and vitamin C, followed by autologous (self) bone marrow stem cell infusion, is safe and effective for treating people with advanced pancreatic cancer who have a BRCA1 or BRCA2 gene mutation.
- NCT04171700: A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes (LODESTAR). This study is looking at how well the PARP inhibitor rucaparib works in people with advanced solid tumors (including breast, ovarian, pancreatic, prostate and other cancers) who have an inherited mutation or an acquired mutation in any of the following genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, NBN and others.
- NCT04666740: Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy. This is a study for people diagnosed with metastatic pancreatic cancer with a tumor test result called HRD-positive, or whose disease has responded well to first-line or second-line platinum therapy. The study will look at whether combining the immunotherapy drug pembrolizumab and the PARP inhibitor olaparib is a more effective treatment for this cancer than taking olaparib alone.
- NCT04858334: Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO). The purpose of EA2192 / APOLLO is to compare the usual approach (observation) to treatment for one year with a drug called olaparib, in patients with a BRCA1, BRCA2 or PALB2 mutation.
- NCT03404960: Niraparib + Ipilimumab or Nivolumab in Pancreatic Cancer that Has Not Progressed After Platinum Chemotherapy (Parpvax). The purpose of this study is to look at the effectiveness, safety and anti-cancer activity of the drug Niraparib (Zejula) combined with one of two immunotherapy drugs—Ipilimumab (Yervoy) or Nivolumab (Opdivo)—on patients with locally advanced or metastatic pancreatic cancer.
- NCT04657068: Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors. This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
A number of other clinical trials for people with pancreatic cancer can be found here.
The following organizations offer peer support services for people with pancreatic cancer
- FORCE peer support
- Our Message Boards allow people to connect with others who share their situation. Once you register, you can post on the Diagnosed With Cancer board to connect with other people who have been diagnosed.
- Peer Navigation Program will match you with a volunteer who shares your mutation and situation.
- Private Facebook Group
- Virtual and in-person support meetings